Discover the new Chem-Impex: Where innovation starts with a bond.

Catalog Number:
38399
CAS Number:
873857-62-6
Fidaxomicin
Purity:
98 - 102% (Assay)
Synonym(s):
Tiacumicin B, Lipiarmycin A3
Documents
$50.00 /25MG
Pack Size Availability Price
Request Bulk Quote
Product Information

Fidaxomicin is a potent macrocyclic antibiotic primarily used in the treatment of Clostridium difficile infections (CDI). Its unique mechanism of action involves inhibiting bacterial RNA polymerase, which effectively disrupts bacterial protein synthesis. This specificity allows Fidaxomicin to target pathogenic bacteria while preserving beneficial gut flora, making it a preferred choice in antibiotic therapy. The compound is particularly valuable in healthcare settings, where the rise of antibiotic resistance necessitates the use of targeted therapies that minimize disruption to the microbiome.

In addition to its clinical applications, Fidaxomicin is being explored for its potential in treating other gastrointestinal infections and conditions. Researchers are investigating its efficacy against various strains of bacteria, highlighting its versatility in combating resistant infections. With its favorable pharmacokinetic profile and low systemic absorption, Fidaxomicin stands out as a safe and effective option for patients, offering a promising solution in the ongoing battle against antibiotic-resistant pathogens.

Synonyms
Tiacumicin B, Lipiarmycin A3
CAS Number
873857-62-6
Purity
98 - 102% (Assay)
Molecular Formula
C52H74Cl2O18
Molecular Weight
1058.05
MDL Number
MFCD27976367
PubChem ID
151383
Melting Point
161 °C (Lit.)
Appearance
White or off-white powder
Conditions
Store at 2 - 8 °C
General Information
Synonyms
Tiacumicin B, Lipiarmycin A3
CAS Number
873857-62-6
Purity
98 - 102% (Assay)
Molecular Formula
C52H74Cl2O18
Molecular Weight
1058.05
MDL Number
MFCD27976367
PubChem ID
151383
Melting Point
161 °C (Lit.)
Appearance
White or off-white powder
Conditions
Store at 2 - 8 °C
Properties
Additional property information coming soon!
-
Safety and Regulations
Hazmat
No
Antibiotic
No
DEA-regulated
No
Warnings
-
Applications

Fidaxomicin is widely utilized in research focused on:

  • Antibiotic Treatment: Primarily used to treat Clostridium difficile infections, offering a targeted approach that minimizes disruption to the gut microbiome compared to broad-spectrum antibiotics.
  • Pharmaceutical Development: Serves as a model compound in the development of new antibiotics, helping researchers understand mechanisms of action and resistance.
  • Clinical Research: Frequently involved in clinical trials to evaluate its efficacy and safety, providing valuable data for healthcare professionals and regulatory bodies.
  • Microbiome Studies: Used in studies examining the impact of antibiotics on gut flora, aiding in the development of therapies that preserve beneficial bacteria.
  • Veterinary Medicine: Investigated for potential applications in treating bacterial infections in animals, offering a specialized alternative to conventional treatments.

Citations